RxDoctor Payments Data

Eryn McMichael

Adult Health · Manassas, VANPI 1225788870

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,378 and has fallen 54.9% since, to $1,073 in 2025. Among adult health clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,404in general payments, 2019–2025

Across 170 payments — averaging $31.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$964
  • Novartis$523
  • AstraZeneca$342
  • Sanofi$341
  • Incyte Corporation$324
  • Exelixis Inc.$215
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$4,95192%
  • Education$4538%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,404 in reported general payments places this provider in the 90th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$35,724
Medicare patients
228
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$12,641
Anastrozole74$1,206
Oxycodone Hcl27$846
Gabapentin44$763
Duloxetine Hcl19$613
Morphine Sulfate ErMorphine Sulfate13$402
Warfarin Sodium12$375
Hydromorphone Hcl16$339
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine24$306
Dexamethasone16$268
Tramadol Hcl38$266
Letrozole13$176
Levothyroxine Sodium18$138
Alprazolam20$128
Pantoprazole Sodium11$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$12,64114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 368 adult health providers in Virginia.

Other adult health in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →